<DOC>
	<DOCNO>NCT01570959</DOCNO>
	<brief_summary>The objective study prove bioequivalence Roxane Laboratories ' Quetiapine Fumarate 300 mg Tablet fast steady state condition .</brief_summary>
	<brief_title>Crossover Bioequivalence Study Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions</brief_title>
	<detailed_description />
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Stable patient DSMIV TR diagnosis schizophrenia . These patient identify via psychiatric evaluation meet DSMIV TR criterion schizophrenia paranoid ( 295.30 ) , disorganize ( 295.10 ) , catatonic ( 295.20 ) , undifferentiated ( 295.90 ) , residual ( 295.60 ) subtype . 2 . Patient significant breakthrough symptom exacerbation psychiatric illness necessitate hospitalization 3 month prior screen . 3 . Patient CGIS score 3 less screening . 4 . On stable regimen treatment include quetiapine fumarate 3 month minimum prior screening , dose quetiapine fumarate total 600 mg total per day minimum 1 month prior screen . Patients qd dose daily quetiapine fumarate must willing convert 300 mg bid dose duration study . 1 . All DSMIV axis I diagnosis , include schizoaffective disorder , schizophreniform disorder and/or psychiatric diagnose opinion principal investigator may conduct trial become primary treatment concern , may interfere patient ability participate trial . 2 . Positive test HIV , Hepatitis B , Hepatitis C. 3 . Treatment known enzyme alter drug . 4 . History allergic adverse response quetiapine comparable similar product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>